The 22 most recent market catalysts affecting $NBIX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target
RBC Capital analyst Brian Abrahams reiterated an 'Outperform' rating and maintained a $198 price target for Neurocrine Biosciences. This action indicates that the analyst's positiv…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Neurocrine Biosciences (NBIX) and raised the price target from $249 to $253. This action signals ongoing analys…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
Neurocrine Biosciences has received FDA Investigational New Drug (IND) acceptance for NBI-1117567, allowing it to proceed with a Phase 2 study for Alzheimer's disease. This is a po…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 85
What's Going On With Neurocrine Biosciences Stock On Wednesday?
Neurocrine Biosciences (NBIX) is facing significant headwinds after reports surfaced regarding deaths and over 100 serious adverse events potentially associated with Vykat XR, a dr…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 65
Neurocrine Biosciences Announces Publication Of Its KINCET-PRO Phase 4 Study Results Showing That Once-Daily INGREZZA Capsules Led To Substantial And Sustained Improvements In Patient-Reported Quality Of Life And Functionality
Neurocrine Biosciences released positive Phase 4 study results for its drug INGREZZA, highlighting improvements in patient-reported quality of life and functionality for tardive dy…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210
Canaccord Genuity analyst Sumant Kulkarni maintained a 'Buy' rating on Neurocrine Biosciences and raised the price target from $200 to $210. This action signals continued bullish s…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213
Truist Securities analyst Danielle Brill has maintained a 'Buy' rating on Neurocrine Biosciences (NBIX) and raised the price target from $200 to $213. This action signals a continu…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194
Wedbush analyst Laura Chico has maintained an 'Outperform' rating on Neurocrine Biosciences (NBIX) and raised the price target from $185 to $194. This action signals continued bull…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $249
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on Neurocrine Biosciences and raised the price target from $246 to $249. This action signals continued positive sentim…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198
RBC Capital analyst Brian Abrahams maintained an 'Outperform' rating on Neurocrine Biosciences (NBIX) and raised the price target from $195 to $198. This action signals continued a…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220
TD Cowen's analyst Phil Nadeau has raised the price target for Neurocrine Biosciences (NBIX) from $200 to $220 while maintaining a 'Buy' rating. This action signals a positive outl…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 85
Neurocrine Biosciences shares are trading lower after the company reported Q2 financial results, and may be falling amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction. The stock previously collaborated with Transthera for NLRP3 inhibitors.
This headline indicates a significant negative catalyst for Neurocrine Biosciences (NBIX) due to its own Q2 financial performance and the 'sympathy' selling stemming from Novo Nord…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $210
Piper Sandler analyst David Amsellem has maintained an 'Overweight' rating on Neurocrine Biosciences (NBIX) and raised the price target from $207 to $210. This action signals conti…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on Neurocrine Biosciences (NBIX) and raised the price target from $210 to $215. This action signals a contin…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $222
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating on Neurocrine Biosciences (NBIX) and raised the price target from $200 to $222. This action signals increased confidence f…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215
Stifel analyst Paul Matteis has maintained a 'Buy' rating on Neurocrine Biosciences and raised the price target from $188 to $215. This upward revision in the price target indicate…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Neurocrine Biosciences, Raises Price Target to $204
Needham analyst Ami Fadia has maintained a 'Buy' rating on Neurocrine Biosciences and raised the price target from $200 to $204. This action signals ongoing analyst confidence in N…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 95
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate
Neurocrine Biosciences reported Q2 adjusted EPS of $2.85, significantly beating the $1.34 estimate by 112.69%, and sales of $959 million, surpassing the $883.259 million estimate b…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Neurocrine Biosciences (NBIX) and raised the price target from $175 to $200. This action signals increased confidence fr…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $200
Wells Fargo's analyst Mohit Bansal maintained an 'Overweight' rating on Neurocrine Biosciences and raised the price target from $175 to $200. This indicates a positive outlook on N…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $200
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Neurocrine Biosciences and significantly raised the price target from $155 to $200. This upgrade indicates inc…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $170
BMO Capital analyst Evan Seigerman maintained a 'Market Perform' rating on Neurocrine Biosciences (NBIX) but raised the price target from $144 to $170. This indicates that while th…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.